20/20 Biolabs, Inc. Common Stock (AIDX)vsEdwards Lifesciences Corp (EW)
AIDX
20/20 Biolabs, Inc. Common Stock
$0.20
+0.25%
HEALTHCARE · Cap: $2.62M
EW
Edwards Lifesciences Corp
$107.15
+1.28%
HEALTHCARE · Cap: $59.81B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 327059% more annual revenue ($6.67B vs $2.04M). EW leads profitability with a 15.3% profit margin vs -285.0%. EW earns a higher WallStSmart Score of 54/100 (C-).
AIDX
Hold36
out of 100
Grade: F
EW
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AIDX.
Margin of Safety
+69.2%
Fair Value
$257.48
Current Price
$107.15
$150.33 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 36.5% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Strong operational efficiency at 30.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -354.6% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AIDX
The strongest argument for AIDX centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 36.5% demonstrates continued momentum.
Bull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 15.3% and operating margin at 30.1%. Revenue growth of 10.5% demonstrates continued momentum.
Bear Case : AIDX
The primary concerns for AIDX are EPS Growth, Market Cap, Return on Equity.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 60.5x leaves little room for execution misses.
Key Dynamics to Monitor
AIDX profiles as a hypergrowth stock while EW is a mature play — different risk/reward profiles.
EW carries more volatility with a beta of 0.83 — expect wider price swings.
AIDX is growing revenue faster at 36.5% — sustainability is the question.
EW generates stronger free cash flow (507M), providing more financial flexibility.
Bottom Line
EW scores higher overall (54/100 vs 36/100), backed by strong 15.3% margins and 10.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
20/20 Biolabs, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
20/20 Biolabs, Inc. (AIDX) is a pioneering biotechnology company dedicated to advancing genomic research and diagnostics through its cutting-edge laboratory services. Focused on improving the accuracy and efficiency of genetic testing for both clinical and research applications, the company is set to establish itself as a leader in the molecular diagnostics market. With a strategic emphasis on personalized medicine and a robust portfolio of state-of-the-art technologies, 20/20 Biolabs is well-positioned to meet the surging demand for genomic data and capitalize on emerging opportunities within the dynamic biotechnology landscape. Its innovative approach and strong market presence reflect a promising growth trajectory in an industry characterized by rapid advancements.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?